Transcatheter arterial chemoembolization combined with molecular targeted therapy for a patient with hepatocellular carcinoma with intrahepatic metastasis and main portal vein tumor thrombus: A case report and literature review

Hepatocellular carcinoma (HCC) is one the most common malignant tumors, with high rates of morbidity and mortality. Surgery is currently the only curative method for HCC. However, many patients are diagnosed with HCC at the advanced stage, and radical resection can no longer be performed. Patients with mildly advanced HCC cannot undergo hepatectomy, and thus transcatheter arterial chemoembolization (TACE) and/or biological targeted therapy are alternative options for these patients. In the present study, we report a patient who showed bene it from the combined treatment of TACE and crizotinib. General clinical data

https://www.heighpubs.org/hcg percussion pain. Regarding the patient's family history, his father had died from lymphadenoma. After hospitalization, the patient underwent magnetic resonance imaging (MRI) and an enhanced examination on 18 June 2018. Multiple intrahepatic lesions were identi ied and were determined as HCC with multiple intrahepatic metastases and right portal tumor thrombus (Figures 1-4A). Serum alpha-fetoprotein (AFP) levels were higher than 1210 ng/mL. No signi icant abnormal lesions were identi ied upon chest CT scan. On 20 June 2018, the patient underwent TACE. Eight milliliters of iodized oil, 40 mg perarubicin, and 50 mg lobaplatin were used during TACE. Gene sequencing revealed that the patient was sensitive to crizotinib, and the patient was administered oral crizotinib 250 mg twice a day. After treatment for 1 month, the patient returned to the hospital for reexamination on 20 July 2018 and underwent an MRI scan and enhanced examination. The results revealed multiple lesions in the liver and sedimented iodine in part of the lesions; the diameters of the lesions had signi icantly decreased compared with the previous lesions and the right portal vein tumor thrombus had disappeared. These results indicated that TACE and oral crizotinib treatment for 1 month caused signi icant shrinkage of the patient's tumors (Figures 1-4). The patient then stopped crizotinib treatment because he was short of funds. On 12 October 2018, the patient returned to the hospital for another reexamination. Serum AFP was 589.2 ng/mL and MRI and enhanced examination identi ied multiple intrahepatic lesions that had increased in number since the previous MRI. The patient died in February 2019.

Discussion
TACE is a common therapy for unresected HCC with portal vein tumor thrombosis and was the irst treatment protocol for moderately advanced HCC [1]. Luo, et al. and Niu, et al. reported a survival rate of more than 1 year for TACE treatment and in a prospective study of TACE treatment for HCC, overall survival was longer in the TACE treatment group than the standard treatment group [2,3]. The blood supply for HCC is mainly from the hepatic artery, while 75% of the blood supply for normal liver tissues is from a portal vein. Thus, tumors that necrotize after chemotherapeutics are perfused into liver tumors via the hepatic artery, while the thromboembolic effects of lipiodol cause the chemotherapeutics to localize in the tumor region. The cytotoxicity of chemotherapeutics and the local ischemia from lipiodol result in synergistic necrosis   of the liver tumor. However, killing all tumor cells is dif icult if chemotherapeutics or lipiodol are used in isolation. Local ischemia and oxygen de icits activate speci ic vascular growth factors, which results in the angiogenesis of tumors, with new vessels and old vessels developing into a lateral branch and increasing the rate of recurrence and metastasis [4]. TACE combined with molecular targeted therapy is a new therapy for moderately advanced HCC and signi icantly decreases postoperative tumor recurrence [5]. In the present study, multiple intrahepatic metastases and right portal vein tumor thrombosis were identi ied in the patient. According to the diagnosis and treatment protocol of HCC in 2017, the patient had no indication for radical resection, and the best treatment for this patient was determined to be TACE combined with molecular targeted therapy.
At present, sorafenib and lenvatinib remain the only therapeutic drugs for moderately advanced HCC. Several clinical experimental studies have demonstrated that treatment with TACE combined with sorafenib could improve the prognosis of patients with HCC [6,7]. In the current patient, the copy number of MET, which encodes a tyrosine kinase receptor that is bound by hepatocyte growth factor as its ligand to activate multiple signaling pathways, was increased. According to the National Comprehensive Cancer Network (NCCN) protocol in 2018, crizotinib was authorized by the FDA for the treatment of non-small cell lung cancer with MET ampli ication and exon 14 skipping. The current patient was administered crizotinib for 1 month (250 mg, P.O, two times/day) after he underwent TACE. An MRI of the upper abdomen was then taken, and liver function and serum AFP were measured during a reexamination on 20 July 2018. The MRI showed that the diameter of the large tumor as well as the number of tumors had decreased, while serum AFP was signi icantly decreased, suggesting a very obvious therapeutic effect of TACE and crizotinib for this patient.
Sorafenib and lenvatinib remain the irst-line therapies for moderately advanced HCC. However, individual differences in pathogenesis, mutagenic genes, recurrence, and metastasis are huge. Genetic testing revealed that the current patient was sensitive to crizotinib, and thus orally administered crizotinib treatment was recommended. While clinical bene its were observed in this patient, the treatment was halted because of insuf icient personal funds.
In conclusion, individualized therapy is a promising therapeutic strategy for moderately advanced HCC.